Webcast Alert: Isis Pharmaceuticals To Provide General Corporate Update in Conjunction...

* Reuters is not responsible for the content in this press release.

Tue May 19, 2009 2:02pm EDT 

Webcast Alert: Isis Pharmaceuticals To Provide General Corporate Update in
Conjunction with 2009 Annual Meeting of Stockholders

CARLSBAD, Calif., May 19 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc.
(Nasdaq: ISIS) announces the following webcast:

    What:   Isis Pharmaceuticals to provide a general corporate update in
            conjunction with the 2009 Annual Meeting of Stockholders.  The
            corporate update will be presented by Stanley T. Crooke, M.D.,
            Ph.D., Chairman and Chief Executive Officer of Isis.

    When:   Tuesday, June 2, 2009, at 6:15 p.m. ET / 3:15 p.m. PT

    Where:  www.isispharm.com

    How:    Live on the Internet.  Simply log onto our Web site listed above.


If you are unable to participate during the live event, a replay of the
webcast will be available for a limited time at www.isispharm.com.

ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its expertise in RNA to discover and develop novel drugs
for its product pipeline and for its partners.  The Company has successfully
commercialized the world's first antisense drug and has 19 drugs in
development.  Isis' drug development programs are focused on treating
cardiovascular and metabolic diseases.  Isis' partners are developing
antisense drugs invented by Isis to treat a wide variety of diseases.  Isis
and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a
company focused on the discovery, development and commercialization of
microRNA therapeutics.  Isis also has made significant innovations beyond
human therapeutics resulting in products that other companies, including
Abbott, are commercializing.  As an innovator in RNA-based drug discovery and
development, Isis is the owner or exclusive licensee of over 1,600 issued
patents worldwide.  Additional information about Isis is available at
www.isispharm.com.

SOURCE  Isis

Kristina Lemonidis, Director, Investor Relations, +1-760-603-2490, or Amy
Blackley, Ph.D., Assistant Director, Corporate Communications,
+1-760-603-2772, both of Isis
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.